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Summary The receptor-type oncogenes c-erbB2/neu and c-erbB have been found amplified and/or
overexpressed in a number of tumours of epithelial origin. We have studied the expression of oncogenes in
biopsies from human thyroid tumours. The c-erbB2/neu and c-erbB oncogenes showed two- to three-fold
higher levels of RNA in papillary carcinomas and lymph node metastases as well as in one adenoma when
compared to non-tumour tissue. The nuclear oncogenes c-myc and c-fos were found to be expressed at
varying levels in both non-tumour and tumour tissue. RNA transcripts specific for the platelet-derived growth
factor A and B chains and the N-ras oncogene were detected in one anaplastic carcinoma. Neither
rearrangements nor amplifications of oncogenes were observed in the thyroid tumours. These data are
particularly interesting in light of the recent findings that epidermal growth factor induces proliferation and
dedifferentiation of normal thyroid epithelial cells in vitro. We suggest that the epidermal growth factor or
other ligands for the c-erbB and c-erbB2/neu receptors may contribute to the development and/or
maintenance of the malignant phentotype of papillary carcinomas of the thyroid.
Strong evidence has accumulated supporting the hypothesis
that abnormalities in either the structure or activity of
proto-oncogenes contribute to the development and/or
maintenance of the malignant phenotype. The expression of
oncogenes has been investigated in several types of human
malignancies, most extensively by Slamon et al. (1984). In
some cases tumour aggressivity and state of differentiation
have been correlated to the expression of certain oncogenes.
The N-myc oncogene has been found abundantly expressed
in poorly differentiated regions of neuroblastomas (Schwab,
1985).
The c-erbB oncogene encodes the receptor for epidermal
growth factor (EGF) (Downward et al., 1984) and
transforming growth factor alpha (TGF-a) (Todaro et al.,
1980). The more recently discovered c-erbB2/neu oncogene is
distinct from, but closely related to c-erbB and encodes a
receptor-like glycoprotein with tyrosine kinase activity for
which a ligand has not yet been identified (Bargmann et al.,
1986; Akiyama et al., 1986; Yamamoto et al., 1986a).
The c-erbB oncogene has been found overexpressed and/or
amplified in a number of cancers of epithelial origin such as
squamous carcinomas (Yamamoto et al., 1986a,b) and in
brain tumours (Libermann et al., 1985). Elevated expression
of the c-erbB2/neu gene has been reported to accompany the
amplification in several instances (King et al., 1985;
Fukushige et al., 1986; Yokota et al., 1986; Kraus et al.,
1987). Recently, the c-erbB2/neu oncogene was found
amplified in a large number of mammary carcinomas, and a
strong correlation between c-erbB2/neu-amplification and
poor prognosis of the disease was observed (Slamon et al.,
1987). The c-fos and c-myc oncogenes have been found
expressed at elevated levels in a wide range of human
tumours (Slamon et al., 1984).
The study of oncogene expression in human tumours may
thus become an important tool in the diagnosis and the
evaluation of prognosis of specific types of malignant
tumours. Thyroid tumours have been largely excluded from
the surveys of oncogene expression in human tumours,
probably due to the low incidence and low mortality from
thyroid cancer. Only recently, evidence was presented for the
existence of a new transforming gene in thyroid papillary
carcinomas and their lymph node metastases (Fusco et al.,
1987). Additionally, thyroid tumours are of particular
interest; firstly, due to the existence of a wide spectrum of
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growth abnormalities, both hyperplastic and neoplastic
which are commonly subjected to surgical removal.
Secondly, thyroid cancer displays non-random geographical
distribution. In Norway, it is most frequent in the coastal
districts (Glattre et al., 1985). Furthermore it will be of
importance to investigate the possible involvement of
oncogenes in the trophic hormone control of the thyroid.
In this paper we report data on the expression of the
receptor-type oncogenes c-erbB and c-erbB2/neu, and the
nuclear oncogenes c-fos and c-myc, in thyroid tumours. Our
data show that c-myc and c-fos are expressed abundantly in
several of the tumours as well as in non-tumour tissue. In
contrast, the highest levels of c-erbB and c-erbB2/neu RNA
expression were found in papillary carcinomas and their
lymph node metastases. In the tumours from the patients so
far tested, neither gross rearrangements nor amplifications of
oncogenes have been detected.
Materials and methods
Enzymes and chemicals
Restriction enzymes were from New England Biolabs. DNA
polymerases and [C_-32P]dATP and [x-32P]dCTP
(3000Ci mmol -1) were from Amersham. Nitrocellulose
membranes (BA-85) were from Schleicher and Schuell.
Guanidinium thiocyanate was from Bethesda Research
Laboratories. All other chemicals were of pro analytical
grade.
Tissue samples
Biopsies were collected from surgically removed thyroid
lobes of patients subjected to either partial or total
thyroidectomy. The samples consisted of both primary
tumour tissue (5 papillary carcinomas, 1 anaplastic carci-
noma, 2 adenomas) and 3 lymph node metastases as well
as 5 samples of non-tumour tissue, including one from a
diffuse toxic goitre. For comparison, a lymphoma of the
thyroid, a mammary carcinoma, and a full term placenta
from a healthy woman were included in the studies (see
Table I for further data on the patients). DNA from a third
adenoma (patient no. 2) was included in the Southern
analysis only. Histological classification was performed by
the Department of Pathology, The Gade Institute, University
of Bergen. All the patients from whom thyroid tissues were
studied, were euthyroid. Three of these patients (nos. 5, 7
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Table I Patient data
Patient
no.a Age Sex Diagnosis
2 31 F Adenoma
5 17 F Papillary carcinoma
7 23 F Diffuse toxic goitre
8 37 F Adenoma
12 81 F Papillary carcinoma
13 35 M Papillary carcinoma
14 37 M Adenoma (Hurtle cell)
15 43 F Papillary carcinoma
17 36 F Papillary carcinoma
19 85 M Anaplastic carcinoma
Ly 83 F Lymphoma of the thyroid
Mc 77 F Mammary carcinoma
aTissue samples from each patient are denoted
by the patient number followed by a sample
number.
and 17) were on thyroxin (0.10-0.20mg per day) for 5-32
weeks prior to surgery. Patient no. 7 was also given a
thyrostatic drug (carbimazole; 30mg per day, 28 weeks prior
to surgery).
Purification ofDNA and RNA from biopsies
Tissue samples taken from thyroid glands or lymph node
metastases immediately after surgical removal from patients
were frozen in liquid nitrogen without delay and thereafter
stored at -80°C until further processing. DNA and total
cellular RNA were simultaneously purified from the biopsies
using a modification of the method described by Chirgwin et
al. (1978) which was briefly as follows: The frozen tissue was
minced briefly (max. 30sec) at 0°C and immediately
transferred to the guanidinium thiocyanate homogenization
solution. The sample was homogenized in a Dounce's homo-
genizer, filtered through cheesecloth, added 1 g CsCl/2.5ml
and layered on top of a 1.25ml cushion of 5.7M CsCl in
0.1 M EDTA. Precipitation of RNA and banding of DNA
was performed by centrifugation at 20°C for 12h at
35,000rpm in a Beckman SW50 rotor. DNA was extracted
twice in phenol/chloroform and once in chloroform, ethanol-
precipitated, and dissolved in 10mM Tris-HCl/l mM
EDTA/pH 7.5. The RNA-pellet was dissolved in 10mM
Tris-HCl/l mM EDTA/1% SDS/pH 7.5, extracted once with
chloroform/n-butanol (4:1), ethanol-precipitated, and stored
at -20°C until further processing. RNA concentration was
determined either spectrophotometrically or by detection of
fluorescence at 590nm in the presence of ethidium bromide
(2.5jgml-1 in PBS; excitation at 360nm).
Hybridization analysis
Restriction enzyme digested DNA was separated by electro-
phoresis on 0.7% agarose gels and blotted onto nitro-
cellulose as described by Maniatis et al. (1982). RNA was
slot-blotted onto nitrocellulose as described by Murnane
(1986) except that denaturation of RNA was carried out
in 12% formaldehyde/105mM sodiumphosphate/105 mM
EDTA/pH 6.5. RNA was separated by electrophoresis in
1 % agarose gels in a MOPS-buffer system in the presence
of 2.2 M formaldehyde and blotted onto nitrocellulose.
Hybridization to immobilized nucleic acids was performed
as described by Maniatis et al. (1982), in the presence of
50% formamide/5xSSC/200 ugml l heat-denatured salmon
sperm DNA/0.1% SDS/25mM sodiumphosphate pH 6.5/
8.25% dextransulphate at 42°C for 15 to 24h. Filters were
washed twice for 20min in 0.2 x SSC/0.1% SDS at 65°C.
When filters were to be rehybridized, the bound probe was
first removed by incubation of the filters in 0.1 x SSC
for 7min at 95-100°C. Kodak XAR-5 X-ray films were
exposed to the nitrocellulose membranes at -80°C in the
presence of intensifying screens. Densitometric scanning of
the films was carried out using a Zeineh soft laser (Biomed
Instruments Inc.) fitted with a HP3390A integrator (Hewlett
Packard).
Preparation ofhybridization probes
DNA fragments were prepared from plasmids and 32P-
labelled by nick translation (Rigby et al., 1977) or using the
oligo-labelling technique (Feinberg & Vogelstein, 1984)
resulting in specific activities ranging from 0.4 to
4x 109cpmpg-1. The probes were purified fragments of
cloned human genes. c-fos: 3kbp XhoI-NcoI fragment of
pc-fos-I (Curran et al., 1983); c-myc: 1.5kbp ClaI-EcoRI
fragment of pE-H8 (Gazin et al., 1984); c-erbB2/neu:
0.44kbp BamHI fragment of pKXO44 (Semba et al., 1985)
and partial cDNA: 1.6kbp EcoRI fragment of pCER204
(Yamamoto et al., 1986a); c-erbB cDNA: 2.4 kbp ClaI frag-
ment of pE7 (Xu et al., 1984); N-ras partial cDNA: 0.55 kbp
EcoRI-SalI fragment of p6al (Taparowsky et al., 1983);
PDGF-A cDNA: 1.3 kbp EcoRI fragment of pUC-13-Dl
(Betsholz et al., 1986); v-sis: 1.2kbp Pstl fragment of pv-sis
(Robbins et al., 1981); thyroglobulin partial cDNA: 0.68
and 0.98kbp PstI fragments of phTgl (Brocas et al., 1982);
Mouse 18S rRNA end-labelled with 32P was a generous gift
from Anne M. Oyan, Department of biochemistry, Uni-
versity of Bergen.
Results
Analysis ofoncogene expression in thyroid tumours
Slot-blot hybridization was the method of choice for
detection of oncogene RNA due to its simplicity and high
sensitivity. Three sets of slot-blotted RNA samples were
prepared. The first set was analyzed by hybridization using
probes for c-myc, c-fos, c-erbB2/neu, thyroblobulin, tubulin
and 18S ribosomal RNA (Figure 1). The second set of slot-
blotted RNA samples were hybridized to probes for c-fos,
c-erbB2/neu (Figure 2), and c-sis, PDGF-A, (Figure 3) and
L-myc (not shown), and the third set was hybridized to
probes for c-myc, c-erbB (Figure 2), and N-ras (Figure 3).
The results from densitometric scanning of the autoradio-
grams are presented in Figure 4.
Expression of c-erbB2/neu and c-erbB
All thyroid biopsies contained c-erbB2/neu and c-erbB RNA.
Three out of 5 papillary carcinomas (13.4, 15.2 and 17.3)
and the 3 lymph node metastases (5.7, 13.5 and 15.3)
expressed these oncogenes at 2- to 3-fold higher levels than
non-tumour tissue. The highest level of c-erbB2/neu RNA
was observed in one of the two adenomas (8.4) while the
anaplastic carcinoma (19.1) expressed low levels of both
c-erbB2/neu and c-erbB RNA.
The c-erbB2/neu probe used in the first experiment (Figure
1) had a low specific activity (7 x 108 cpmjug-l) and the
signals are barely visible; high levels of c-erbB2/neu specific
RNA in this experiment were, however, observed in the two
metastases (5.7 and 13.5). These results were confirmed in
the second hybridization experiment (Figure 2).
Among the non-thyroid biopsies, the mammary carcinoma
(Mc) expressed more than 18-fold higher levels of c-erbB2/
neu RNA than the non-tumour tissues, whereas c-erbB RNA
was not detected. This tumour exhibited a more than 20-
fold amplification of the c-erbB2/neu gene (Figure 5). The
placenta expressed high levels of c-erbB but not c-erbB2/neu.
Expression ofc-myc and c-fos
All thyroid biopsies contained high levels of c-myc and c-fos
RNA. The anaplastic carcinoma (19.1) expressed highest
level of c-myc RNA while a lymph node metastasis (15.3)360 R. AASLAND et al.
Biopsy myc fos erbB-2 Tg tubulin rRNA
Figure 1 Expression of the c-myc, c-fos, c-erbB2/neu oncogenes,
thyroglobulin, and tubulin in 3 thyroid tumours, a thyroid
lymphoma, and a term placenta from a healthy woman. Samples
of 20pg total RNA was slot-blotted onto nitrocellulose
membranes and hybridized to the probes indicated as described
in Materials and methods. An end-labelled mouse 18S rRNA was
used as a probe to evaluate the amount of RNA applied to the
filter. PC: Papillary carcinoma; LM: Lymph node metastasis; Ly:
Lymphoma; P: Placenta.
Biopsy
no.
7.3 NT
7.4 NT
8.1 NT
8.4 AD
12.1 PC
12.2 PC
13.5 LM
14.2 NT
14.5 AD
15.1 NT
15.2 PC
15.3 LM
17.2 NT
17.3 PC
19.1 AC
19.2 AC
p
p
myc fos erb-B erb-B2
Ly
Mc
Figure 2 Expression of c-myc, c-fos, c-erbB, and c-erbB2/neu in
biopsies from thyroid tumours and non-tumour thyroid tissue, a
thyroid lymphoma, a mammary carcinoma and a term placenta
from a healthy woman. Samples of 12pg total RNA was slot-
blotted onto nitrocellulose membranes and hybridized to the
probes indicated. NT: non-tumour tissue; AD: adenoma; AC:
anaplastic carcinoma; PC: papillary carcinoma; M: lymph node
metastasis; Ly: lymphoma; Mc: mammary carcinoma; P:
placenta; 0: RNA not applied. Sample no. 19.2 was disregarded
due to loss of RNA during sample preparation.
exhibited highest level of c-fos RNA. Notably, several
samples of non-tumour tissue contained high levels of c-myc
and c-fos RNA. It should also be noted that elevated
expression of c-fos was observed in the three papillary
carcinomas (13.4, 15.2 and 17.3) expressing the highest levels
of c-erbB2/neu and c-erbB specific RNA.
Figure 3 Expression of c-sis, N-ras and PDGF-A specific RNA
in an anaplastic carcinoma (19.1). The same RNA slot-blots
(12.ug RNA per slot) as used in Figure 2 have been rehybridized
to the probes as indicated.
The integrity of the RNA was sufficiently maintained as
indicated by the presence of the 2.2 and 2.0kb c-fos
transcripts on a Northern blot (Figure 6). The low sensitivity
in this experiment allowed detection of transcripts only in
the four samples from Patients no. 12 and 13. Slight
smearing of the fos-transcripts was apparent, indicating that
some degradation of RNA had occured. This had most
probably taken place during the lengthy and complicated
surgical removal of the thyroid. A slight degradation of
RNA should not, however, seriously affect the detection of
slot blotted RNA.
Expression ofother genes
N-ras, c-sis and PDGF-A specific RNA was expressed at
low but invariant levels in all the thyroid samples (data not
shown) except in the anaplastic carcinoma (19.1). This
tumour showed 4-fold higher levels of N-ras and PDGF-A
RNA as well as traces of c-sis RNA than the other thyroid
samples as determined by densitometric scanning of auto-
radiograms (Figure 3). This tumour may therefore produce
homo- as well as heterodimers of PDGF. L-myc expression
was not detected in any of the samples tested (not shown).
Thyroglobulin specific RNA was expressed at very high
levels in all the thyroid samples while being completely
absent from the lymphoma and the placenta (Figure 1). To
serve as an internal control, the filter was rehybridized to a
tubulin and a mouse 18S rRNA probe (Figure 1). The
results clearly demonstrate that the level of tubulin RNA
varied to a great extent among the tissue specimens and thus
was of little value as an internal control. The 18S rRNA
hybridization indicated that the amount of RNA applied to
the filter varied only slightly.
Southern blot-hybridization to tumour DNA
In Figure 6 the Southern blot analysis of various thyroid
tumour DNAs using the c-erbB2/neu probe is shown.
Neither amplification nor rearrangements were found. In
contrast, the c-erbB2/neu gene was amplified more than 20-
fold in the mammary carcinoma (Mc).
Restriction fragment analyses of the c-myc, c-fos, and c-
erbB oncogenes as well as others (including c-myb, c-etc-i, c-
src, int-i and p53) have also been carried out with DNA
from the thyroid tumours. No rearrangements nor
amplifications have so far been detected (results not shown).
Discussion
We have studied the expression of oncogenes in fresh
biopsies from 8 patients having different types of thyroid
tumours and in biopsies from a diffuse toxic goitre and a
lyphoma of the thyroid. The expression of the c-erbB and
c-erbB2/neu oncogenes was found to be 2- to 3-fold higher in
3 of 5 papillary carcinomas, 3 lymph node metastases, and
one adenoma than in non-tumour tissue and the anaplastic
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Figure 4 Relative levels of oncogene expression as measured by densitometric scanning of the autoradiograms shown in Figures 1
and 2. The units of expression are arbitrary. The biopsies are grouped according to histological classification as follows: NT: non-
tumour; PC: Papillary carcinoma; AC: Anaplastic carcinoma; AD: Adenoma; OT: other tissues; P: Placenta; Ly: Lymphoma; Mc:
Mammary carcinoma. (nd: not determined).
carcinoma. Our data extend the list of human tumours in
which an elevated expression of the c-erbB2/neu and c-erbB
oncogenes is found also to include papillary carcinomas of
the thyroid. To decide whether this is a feature of these
carcinomas in general, will require further data. The
expression of c-erbB2/neu in the thyroid samples was
moderate as compared to the mammary carcinoma that
contained a >20-fold amplified c-erbB2/neu gene. Inter-
mediate level expression of these receptor type oncogenes
may, nevertheless, be important. The A431 epidermoid
carcinoma cells which are expressing very high levels of
EGF-receptors have been found to be inhibited by EGF at
concentrations which are mitogenic to other cells (Gill &
Lazar, 1981; Barnes, 1982). An elevated expression of these
oncogenes at the RNA level does not imply that the cells
express higher levels of functional receptors, although this
is most likely. The expression of c-erbB was clearly evident
in non-tumour thyroid tissue. This finding is supported by
the observation by Humphries et al. (1983) that normal
thyroid epithelial cells possess EGF-receptors. It has recently
been shown by several groups that EGF induces prolifera-
tion and dedifferentiation of normal thyroid epithelial
cells in culture (Eggo et al., 1984; Roger & Dumont,
1984; Westermark et al., 1983; Waters et al., 1987). Thus it
is possible that an elevated expression of EGF-receptors
contributes to the development of a malignant phenotype
of thyroid tumours by increasing proliferation and de-
differentiation. Pertinent to this are the reports on the
induction by EGF of plasminogen activator which in turn
may lead to the degradation of extracellular matrix proteins
(Lee & Weinstein, 1978; Stoppelli et al., 1986). In mammary
carcinomas, there is now evidence for the expression of
TGF-a and its possible involvement in an autocrine or
paracrine stimulation of growth (Dickson et al., 1987). An
increased level of EGF-receptors may potentiate such
stimulation. We are currently investigating whether TGF-oc is
expressed in the thyroid tumours. Although EGF did not
stimulate the tyrosine kinase activity of the c-erbB2/neu
protein, EGF induced tyrosine and serine phosphorylation of
the c-erbB2/neu protein (Akiyama et al., 1986; Kadowaki et
al., 1987). This suggests that the coexpression of the c-
erbB2/neu and c-erbB oncogenes in the thyroid tumours
demonstrated in the present report, may have functional
relevance.
The c-myc and c-fos oncogenes were expressed at varying
levels in tumour tissue as well as in non-tumour tissue. There
was no correlation with the expression of these two
oncogenes and the type of thyroid tumour. High levels of
c-myc and c-fos RNA have been reported in a wide range of
human tumours (Slamon et al., 1984). Our data add thyroid
tumours to this list. The presence of elevated levels of c-myc
and c-fos RNA in the non-tumour tissue samples indicates
that expression of these genes does not imply malignancy.
One should note, however, that the non-tumour biopsies
were taken from tumour-bearing thyroids (except the one
from a diffuse toxic goitre). It is possible that the entire
tumour-bearing thyroids were in a state of growth-
stimulation that could induce the expression of c-myc and
c-fos as has been shown in vitro (Dere et al., 1985;
Tramontano et al., 1986; Colletta et al., 1986). Furthermore,
the expression of these genes may be unevenly distributed in
the tumours, and we are currently investigating this
possibility by means of in situ hybridization.
The anaplastic carcinoma exhibited a markedly different
pattern of oncogene expression when compared to the
papillary carcinomas. In particular, the c-myc and N-ras
oncogenes were expressed at high levels. The anaplastic
carcinoma may be an example of a tumour in which the
action of these two oncogenes contributes to the trans-
formation in a cooperative manner (Land et al., 1983). This
tumour also expressed RNA specific for the A and B chains
of PDGF. These differences may reflect the different
properties of these two types of tumours, the anaplastic
carcinomas being far more aggressive than the papillary
carcinomas.
In a separate line of studies using oligonucleotide
c-erbB2/
neu
c-erbB
c-fos
c-myc362 R. AASLAND et al.
P 2.2 2.4 Mc 13.2 13.4
2.3
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0.56- .
Figure 5 Southern blot of DNA from 4 thyroid tissue
specimens, a mammary carcinoma, and a placenta hybridized to
a c-erbB2/neu probe. Size markers are phage lambda HindlIl
fragments. P: Placenta; Mc: Mammary carcinoma.
hybridization, we have looked for point-mutations in codon
12 of the c-K-ras oncogene in the thyroid tumours. No such
mutations have been detected (Rusken & Aasland, un-
published observations). Neither have we found any gross
rearrangements not amplifications of oncogenes in the
12.1 12.2 13.4 13.5 kb
2.2
| __ _ | | l -i !l_
Figure 6 Hybridization with the c-fos probe to a Northern blot
ot total cellular RNA from four samples of thyroid tumour
tissue. The sizes of the transcripts were determined relative to
radioactively labelled phage lambda HindII fragments.
thyroid tumours investigated and, in particular no amplifi-
cations of the c-erbB and c-erbB2/neu oncogenes were
observed. The deregulation of these genes in thyroid tumours
may thus be due to molecular mechanisms other than genetic
alterations of these genes. Kraus and coworkers (1987) also
observed elevated expression of the c-erbB2/neu gene in
several mammary tumour cell lines that did not exhibit an
amplified gene.
Further studies on the expression and regulation of the
c-erbB and c-erbB2/neu genes in malignant and non-
malignant thyroid tumours will shed light on the role of
these oncogenes in the development and maintenance of a
malignant phenotype.
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